We are excited to welcome Phialogics as our newest portfolio company!
Basel, Switzerland. 20 September 2022 – Phialogics is a preclinical stage company developing cell-type-specific immune checkpoint activators to prevent multi-organ failure in autoimmune diseases.
Based on research concepts established at the Fraunhofer Institute of Translational Medicine and Pharmacology ITMP, and the Medical Faculty of the Goethe-University Frankfurt in Germany, the company engineers next generation biologics that rebalance the immune response in acute and chronic inflammation.
Phialogics business idea is the result of a long and successful collaboration between Andreas Ernst, Pascal Oromi, Michael Parnham, Andreas Weigert and Andreas von Knethen. Each founding partner brings a unique skill set with experience in industry and R&D that complement each other.
